

Department of Chest Diseases,
School of Medicine, Karadeniz
Technical University, Trabzon,

¹Chest Disease Clinic,

Pulmonary Diseases Hospital,
Balıkesir, ²Department of

Pulmonary Diseases, Dr. Suat
Seren Pulmonary Diseases and
Thoracic Surgery Education

and Research Hospital, Izmir,

³Department of Pulmonary
Diseases, Sureyyapasa
Pulmonary Diseases and

Thoracic Surgery Education
and Research Hospital,

Istanbul, ⁴Department of Chest
Diseases, School of Medicine,

Bulent Ecevit University,

Zonguldak, ⁵Department of

Chest Diseases, School of

Medicine, Gaziosmanpasa

University, Tokat, ⁶Department

of Chest Diseases, School

of Medicine, Yuzuncu Yil

University, Van, ⁷Chest Disease

Clinic, Tosya State Hospital,

Kastamonu, ⁸Department

of Chest Diseases, School

of Medicine, Recep Tayyip

Erdogan University, Rize,

⁹Department of Chest

Diseases, School of Medicine,

Kırıkkale University,

Kırıkkale, ¹⁰Department of

Pulmonary Diseases, Diskapi

Yildirim Beyazid Education

and Research Hospital,

¹¹Department of Chest

Diseases, School of Medicine,

Hacettepe University, Ankara,

¹²Department of Pulmonary

Diseases, Konya Education

and Research Hospital, Konya,

¹³Chest Disease Clinic, Afyon

State Hospital, Afyon, Turkey

**Address for
correspondence:**

Prof. Yilmaz Bulbul,
Department of Chest
Diseases, School of
Medicine, Karadeniz
Technical University,
61080 Trabzon, Turkey.
E-mail: bulbulyilmaz@
yahoo.com

Submission: 13-05-2018

Accepted: 21-07-2018

Access this article online

Quick Response Code:



Website:

www.thoracicmedicine.org

DOI:

10.4103/atm.ATM_145_18

Immunization status in chronic obstructive pulmonary disease: A multicenter study from Turkey

Tevfik Ozlu, Yilmaz Bulbul, Derya Aydin¹, Dursun Tatar², Tulin Kuyucu³, Fatma Erboy⁴, Handan Inonu Koseoglu⁵, Ceyda Anar², Aysel Sunnetcioglu⁶, Pinar Yildiz Gulhan⁷, Unal Sahin⁸, Aydanur Ekici⁹, Serap Duru¹⁰, Sevinc Sarinc Ulasli¹¹, Ercan Kurtipek¹², Sibel Gunay¹³ and RIMPACT Study Investigators*

Abstract:

OBJECTIVE: The purpose of this study is to detect the prevalence and the factors associated with influenza and pneumococcal vaccination and outcomes of vaccination during 2013–2014 season in patients with chronic obstructive pulmonary disease (COPD) in Turkey.

METHODS: This was a multicenter retrospective cohort study performed in 53 different centers in Turkey.

RESULTS: During the study period, 4968 patients were included. COPD was staged as GOLD 1-2-3-4 in 9.0%, 42.8%, 35.0%, and 13.2% of the patients, respectively. Influenza vaccination rate in the previous year was 37.9%; and pneumococcus vaccination rate, at least once during in a life time, was 13.3%. Patients with older age, higher level of education, more severe COPD, and comorbidities, ex-smokers, and patients residing in urban areas had higher rates of influenza vaccination. Multivariate logistic regression analysis showed that advanced age, higher education levels, presence of comorbidities, higher COPD stages, and exacerbation rates were associated with both influenza and pneumococcal vaccination. The number of annual physician/outpatient visits and hospitalizations due to COPD exacerbation was 2.73 ± 2.85 and 0.92 ± 1.58 per year, respectively. Patients with older age, lower education levels, more severe COPD, comorbid diseases, and lower body mass index and patients who are male and are residing in rural areas and vaccinated for influenza had significantly higher rates of COPD exacerbation.

CONCLUSIONS: The rates of influenza and pneumococcal vaccination in COPD patients were quite low, and the number of annual physician/outpatient visits and hospitalizations due to COPD exacerbation was high in Turkey. Advanced age, higher education levels, comorbidities, and higher COPD stages were associated with both influenza and pneumococcal vaccination.

Keywords:

Chronic obstructive pulmonary disease, chronic obstructive pulmonary disease exacerbation, influenza vaccine, pneumococcal vaccine

Chronic obstructive pulmonary disease (COPD) is highly prevalent illness, and the prevalence varies throughout the world. An overall COPD prevalence of 7.8%–19.7% is reported in adult population.^[1-7] Patients usually suffer from cough, sputum, dyspnea,

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

and sometimes acute worsening of these symptoms, termed as COPD exacerbation, especially in winter season. Acute COPD exacerbations, which can lead to more frequent physician/hospital admissions, hospitalizations, life-threatening complications, and death, are mostly associated with tracheobronchial infections and air pollution.^[8] Acute exacerbations are

How to cite this article: Ozlu T, Bulbul Y, Aydin D, Tatar D, Kuyucu T, Erboy F, *et al.* Immunization status in chronic obstructive pulmonary disease: A multicenter study from Turkey. *Ann Thorac Med* 2019;14:75-82.

For reprints contact: reprints@medknow.com

more common in severe COPD cases, and those cases are reported to be referred to the hospital 1.5–2.5 times per year.^[9]

Of the infectious COPD exacerbations, 40%–60% are known to be related to bacterial infections and 30% are related to respiratory viral infections (rhinoviruses, influenza viruses, etc.).^[10] Influenza vaccination has been shown to reduce outpatient visits, hospitalizations, and mortality rates due to COPD exacerbations.^[11,12] Pneumococcal vaccine has also been shown to decrease pneumococcal pneumonia in COPD patients.^[13,14] In current practice, GOLD guidelines recommend influenza vaccination in all COPD patients to reduce serious illness.^[15] Similarly, conjugate and polysaccharide (PCV13 and PPSV23, respectively) pneumococcal vaccines are recommended for all COPD patients aged ≥ 65 years. PPSV is also recommended for younger patients (< 65 years) with significant comorbid conditions including chronic heart or lung diseases.^[15]

The purpose of this study is to detect the prevalence and the factors associated with influenza and pneumococcal vaccination and outcomes of vaccination during 2013–2014 season in COPD patients in Turkey.

Methods

Study design

This multicenter retrospective cohort study was carried out in 53 different centers in Turkey between December 1, 2014, and January 31, 2015, following approval by the ethics committee.

Study population

During the study period, all patients (> 40 years of age) who were admitted to these centers with at least 1 year history of COPD, diagnosed according to the GOLD criteria, and agreed to participate in the study were included.^[15] Demographic characteristics and patients symptoms were collected, and modified Medical Research Council (mMRC) dyspnea scale was filled for each patient by physicians using a standard questionnaire, which was completed by face-to-face interviews. Whether patients had influenza vaccination in the recent year (Have you been vaccinated for influenza in the last year?) and pneumococcal vaccination at least once in a lifetime (Have you ever received the pneumococcal vaccine?) were questioned. COPD exacerbation was defined as worsening of respiratory symptoms requiring a physician or a hospital visit or hospitalization (How many times have you been admitted to a physician or a hospital due to worsening of your respiratory symptoms?/How many times have you been hospitalized due to worsening of your respiratory symptoms?). Physician/hospital visits

and/or hospitalizations due to COPD exacerbation were also recorded.

Statistical analysis

Data analysis was performed using SPSS software (version 13.01, SPSS Inc., Chicago, IL, USA). The Chi-square test was used to compare categorical variables. The Kolmogorov–Smirnov test was used to test for normal distribution of variables. The parametric student's *t*-test was used for comparing mean or median values of normally distributed data, and the nonparametric Mann–Whitney U-test was used to compare data that were not normally distributed. Factors that were potential contributors to vaccination (age, gender, education, smoking, body mass index, residential area, comorbidities, and COPD severity) were analyzed using logistic regression. Multivariate logistic regression analysis was used as a stepwise descending method from predictive factors with a significance < 0.05 in the univariate analysis.

Results

A total of 5135 patients were collected from the study centers. However, after exclusion of 167 patients due to younger age (≤ 40 years), repeated records, and patients with missing data, 4968 patients were analyzed. Of all patients, 4196 were male (84.5%) and the mean age was a 66.5 ± 10.0 years (male: 66.6 ± 9.8 , female: 66.1 ± 10.7). Other demographic characteristics are summarized in Table 1.

Influenza and pneumococcal vaccination rate

Overall rate of influenza vaccination was 37.9% (1885/4968, 95% confidence interval [CI]: 0.366–0.393) during 2013–2014 seasons. Vaccination rates were 41.4% (852/2060, 95% CI: 0.392–0.435) and 39.7% (324/816, 95% CI: 0.364–0.431) in COPD D and C and 36.0% (363/1009, 95% CI: 0.330–0.389) and 32.4% (343/1059, 95% CI: 0.296–0.352) in COPD B and A, respectively ($P < 0.001$). Patients with older age, higher education, more severe COPD, and comorbid diseases and also patients who are ex-smokers and residing in urban area had significantly higher rates of influenza vaccination [Table 1].

Overall rate of pneumococcal vaccination was 13.3% (659/4966, 95% CI: 0.123–0.142) at least once during in a life time. Similar to influenza, pneumococcal vaccination rates were also significantly higher in ex-smokers (15.1% vs. 9.1%, $P < 0.001$), patients with higher education (university: 29.8%, secondary/high school: 20.0%, elementary school: 11.3% vs. uneducated: 8.3%, $P < 0.001$), patients with comorbid diseases (15.4% vs. 10.4%, $P < 0.001$), and patients residing in urban area (15.1% vs. 8.8%, $P < 0.001$), except COPD severity (COPD D: 15.2%, COPD C: 12.3%, COPD B:

Table 1: Demographic characteristics of chronic obstructive pulmonary disease patients according to the influenza vaccination status

Variables	Influenza vaccinated, n (%)	Influenza unvaccinated, n (%)	Total, n (%)	P
Age (4968 patients)				
<65years	666 (35.3)	1358 (44.0)	2024 (40.7)	<0.001
≥65 years	1219 (64.7)	1725 (56.0)	2944 (59.3)	
Gender (4968 patients)				
Male	1609 (85.4)	2587 (83.9)	4196 (84.5)	0.172
Female	276 (14.6)	496 (16.1)	772 (15.5)	
Education (4967 patients)				
Uneducated	220 (11.7)	537 (17.4)	757 (15.2)	<0.001
Elementary school	1127 (59.8)	1965 (63.8)	3092 (62.3)	
Secondary/high school	404 (21.4)	479 (15.5)	883 (17.8)	
University	134 (7.1)	101 (3.3)	235 (4.7)	
Smoking (4957 patients)				
Nonsmoker	212 (11.3)	374 (12.2)	586 (11.8)	<0.001
Ex-smoker	1319 (70.1)	1775 (57.7)	3094 (62.4)	
Smoker	351 (18.7)	926 (30.1)	1277 (25.8)	
Residence (4933 patients)				
Rural	489 (26.2)	941 (30.7)	1430 (29.0)	0.001
Urban	1379 (73.8)	2124 (69.3)	3503 (71.0)	
mMRC score (4967 patients)				
0	90 (4.8)	158 (5.1)	248 (5.0)	0.004
1	530 (28.1)	1021 (33.1)	1551 (31.2)	
2	504 (26.7)	760 (24.7)	1264 (25.4)	
3	506 (26.8)	743 (24.1)	1249 (25.1)	
4	255 (13.5)	400 (13.0)	655 (13.2)	
GOLD category (4608 patients)				
GOLD 1	152 (8.7)	264 (9.3)	416 (9.0)	0.007
GOLD 2	708 (40.3)	1264 (44.3)	1972 (42.8)	
GOLD 3	634 (36.1)	979 (34.3)	1613 (35.0)	
GOLD 4	262 (14.9)	345 (12.1)	607 (13.2)	
GOLD groups (4769 patients)				
Group A	394 (22.0)	785 (26.4)	1179 (24.7)	0.004
Group B	343 (19.2)	542 (18.2)	885 (18.6)	
Group C	220 (12.3)	385 (12.9)	605 (12.7)	
Group D	833 (46.5)	1267 (42.5)	2100 (44.0)	
Comorbidity (patients)				
At least one (4968)	1181 (62.7)	1701 (55.2)	2882 (58.0)	<0.001
Hypertension (4836)	723 (39.6)	982 (32.6)	1705 (35.3)	
Heart failure (4913)	299 (16.1)	414 (13.5)	713 (14.5)	0.013
Diabetes mellitus (4812)	345 (19.0)	405 (13.5)	750 (15.6)	<0.001
Allergy-Atopy (4876)	224 (12.1)	332 (11.0)	556 (11.4)	0.206
Other (2810)	462 (40.6)	688 (41.1)	1150 (40.9)	0.795
COPD exacerbation				
Exacerbation ≥2	1053 (58.8)	1653 (55.5)	2706 (56.7)	0.023
Exacerbation <2	737 (41.2)	1327 (44.5)	2064 (43.3)	
BMI (4863 patients)*				
Low	131 (7.1)	229 (7.6)	360 (7.4)	0.417
Normal	590 (31.8)	1013 (33.7)	1603 (33.0)	
Overweighed	678 (36.5)	1061 (35.3)	1739 (35.8)	
Obese	456 (24.6)	705 (23.4)	1169 (23.9)	

*Low (BMI <20 kg/m²), Normal (BMI: 20-24.9 kg/m²), Overweighed (BMI: 25-29.9 kg/m²), Obese (BMI ≥30 kg/m²). BMI=Body mass index, COPD=Chronic obstructive pulmonary disease, mMRC=Modified Medical Research Council, GOLD=Global Initiative for Chronic Obstructive Pulmonary Disease

13.9%, and COPD A: 14.4%, $P = 0.270$). Furthermore, female patients had significantly higher rates of pneumococcal vaccination (16.0% vs. 12.8%, $P = 0.017$).

Multivariate logistic regression analysis showed that advanced age (odds ratio [OR]: 1.519, 95% CI: 1.327–1.738, $P < 0.001$ and OR: 1.309, 95% CI: 1.084–1.580,

$P = 0.005$), higher education levels (OR: 4.217, 95% CI: 2.990–5.947, $P < 0.001$ and OR: 6.200, 95% CI: 4.033–9.533, $P < 0.001$), presence of comorbidities (OR: 1.207, 95% CI: 1.060–1.374, $P = 0.004$ and OR: 1.357, 95% CI: 1.126–1.635, $P < 0.001$), and higher COPD stages and exacerbation rates (OR: 1.175, 95% CI: 1.028–1.342, $P = 0.018$ and OR: 1.518, 95% CI: 1.263–1.824, $P < 0.001$) were found to be associated with both influenza and pneumococcal vaccination, respectively [Table 2]. Multivariate logistic regression analysis also showed female gender as a factor that contributing to (OR: 1.675, 95% CI: 1.288–2.178, $P < 0.001$) pneumococcal vaccination. On the contrary, active smoking was associated with lower influenza and pneumococcal vaccination rates (OR: 0.638, 95% CI: 0.501–0.813, $P < 0.001$ and OR: 0.679, 95% CI: 0.474–0.972, $P = 0.034$).

Among influenza-vaccinated patients, 86.3% (1627/1885, 95% CI: 0.846–0.877), 6.3% (119/1885, 95% CI: 0.053–0.075), and 7.3% (139/1885, 95% CI: 0.062–0.086) said that they had been vaccinated after the recommendation of their physicians, pharmacists, or others, respectively. In contrast, among the patients unvaccinated, 53.1% (1645/3026, 95% CI: 0.525–0.561) stated that their physician did not recommend vaccination, 12.6% (390/3026, 95% CI: 0.117–0.141) said that the vaccine was ineffective, and 34.3 (991/3026, 95% CI: 0.311–0.344) reported other reasons.

Annual chronic obstructive pulmonary disease exacerbation and hospitalization rates

Annual number of COPD exacerbation requiring physician/outpatient visit was 2.73 ± 2.85 times per year and requiring hospitalization was 0.92 ± 1.58 times per year. Patients with older age (>65), lower education

levels, more severe COPD, comorbid diseases, and lower BMI and patients who are male and are residing in rural area and vaccinated for influenza had significantly higher rates of COPD exacerbation rates [Table 3].

Discussion

In this study, we found that the overall prevalence of influenza vaccination among COPD patients during 2013–2014 season was 37.9% and pneumococcal vaccination at least once in a lifetime was 13.3%. A recent study which was performed in western cities of Turkey showed similar vaccination rates (36.5% for influenza and 14.1% for the pneumococcus).^[16] Influenza and pneumococcus vaccination rates were found to be unchanged during this 8-year period after a study which was performed in Eastern Black Sea Region of Turkey during 2006/2007 season, and in that previous study, vaccination rates were detected as 33.3% and 12.0%, respectively.^[17] Despite vaccine recommended groups are well defined and vaccines were reimbursed by Social Security Institution, vaccination rates remain low in Turkey. There are varying vaccination rates in COPD patients worldwide. In the PLATINO study which was conducted in 2003 in five different Latin American countries, influenza vaccination rate reported to be lower in Caracas (Venezuela) and higher in Santiago (Chile) as 5.1% and 52%, respectively.^[18] A study from Italy by Chiatti *et al.* showed that the influenza vaccination rate to be 30.5% during 2004/2005 season.^[19] One another study from Germany showed 46.5% of patients received influenza vaccine and 14.6% received pneumococcal vaccine during 2002/2003 season.^[20] On the other hand, higher influenza vaccination rates were reported from Norway (59%, during 2006/2007 season) and from

Table 2: Multivariate logistic regression analysis of demographic parameters contributing influenza and pneumococcal vaccination

Variables*	Influenza vaccination			Pneumococcal vaccination		
	OR	95.0% CI	P	OR	95.0% CI	P
Age ≥ 65 years	1.519	1.327-1.738	<0.001	1.309	1.084-1.580	0.005
Gender (female)	-	-	-	1.675	1.288-2.178	<0.001
Residence (Urban area)	0.934	0.807-1.082	0.364	1.526	1.218-1.911	<0.001
Education						
Uneducated	Reference	-	-	Reference	-	-
Elementary school	1.538	1.247-1.897	<0.001	1.704	1.235-2.351	0.001
Secondary/high school	2.563	1.996-3.291	<0.001	3.625	2.531-5.193	<0.001
University	4.217	2.990-5.947	<0.001	6.200	4.033-9.533	<0.001
Smoking						
Nonsmoker	Reference	-	-	Reference	-	-
Ex-smoker	1.118	0.902-1.387	0.309	1.164	0.841-1.611	0.361
Smoker	0.638	0.501-0.813	<0.001	0.679	0.474-0.972	0.034
Comorbidity	1.207	1.060-1.374	0.004	1.357	1.126-1.635	<0.001
COPD exacerbation ≥ 2	1.175	1.028-1.342	0.018	1.518	1.263-1.824	<0.001
GOLD grade (3 and 4)	1.232	1.082-1.403	0.002	-	-	-

*Only variables, derived from predictive factors with a significance ≤ 0.05 in the univariate analysis, were included. COPD=Chronic obstructive pulmonary disease, CI=Confidence interval, OR=Odds ratio, GOLD=Global Initiative for Chronic Obstructive Pulmonary Disease

Table 3: The number of physician/policlinic visits and hospitalizations due to chronic obstructive pulmonary disease exacerbations per year

Variables*	Number of exacerbation/year		P	Number of hospitalization/year		P
	Mean±SD	Median-range		Mean±SD	Median-range	
Age (years)						
<65	2.40±2.69	2 (0-12)	<0.001	0.70±1.40	0 (0-12)	<0.001
≥65	2.95±2.94	2 (0-12)		1.07±1.67	0 (0-12)	
Gender						
Male	2.89±2.81	2 (0-12)	0.005	0.90±1.49	0 (0-12)	0.581
Female	2.70±2.86	2 (0-12)		0.92±1.59	0 (0-12)	
Education						
Uneducated	3.82±3.16	3 (0-12)	<0.001	1.51±1.92	1 (0-12)	<0.001
Elementary school	2.80±2.88	2 (0-12)		0.94±1.59	0 (0-12)	
Secondary/high school	1.98±2.35	1 (0-12)		0.54±1.18	0 (0-10)	
University	1.35±1.70	1 (0-10)		0.31±0.77	0 (0-5)	
Residence						
Rural	3.30±3.02	2 (0-12)	<0.001	1.28±1.78	1 (0-10)	<0.001
Urban	2.49±2.75	2 (0-12)		0.78±1.47	0 (0-12)	
GOLD category						
GOLD 1	1.73±2.18	1 (0-1)	<0.001	0.34±0.91	0 (0-8)	<0.001
GOLD 2	2.01±2.38	1 (0-12)		0.53±1.12	0 (0-10)	
GOLD 3	3.02±2.90	2 (0-12)		1.06±1.65	0 (0-12)	
GOLD 4	4.27±3.24	3 (0-12)		1.78±1.96	1 (0-10)	
GOLD groups						
Group A	0.42±0.49	0 (0-1)	<0.001	0.07±0.26	0 (0-2)	<0.001
Group B	0.57±0.49	1 (0-1)		0.20±0.40	0 (0-1)	
Group C	3.43±2.05	3 (2-12)		0.67±1.12	0 (0-8)	
Group D	4.74±2.82	4 (2-12)		1.77±1.96	1 (0-12)	
Comorbidity (patients)						
At least one co-morbidity	2.85±2.89	2 (0-12)	<0.001	1.00±1.63	0 (0-12)	<0.001
Hypertension (4836)	2.98±2.94	2 (0-12)	<0.001	1.06±1.67	0 (0-12)	<0.001
Heart failure (4913)	3.24±3.02	2 (0-12)	<0.001	1.18±1.70	1 (0-12)	<0.001
Diabetes mellitus (4812)	3.08±2.95	2 (0-12)	<0.001	1.25±1.96	1 (0-10)	<0.001
Allergy-Atopy (4876)	2.90±2.89	2 (0-12)	0.105	0.77±1.42	0 (0-10)	0.001
Other (2810)	2.64±2.88	2 (0-12)	<0.001	0.88±1.52	0 (0-10)	0.015
BMI*						
Low	3.16±2.93	2 (0-12)	0.011	1.20±1.64	1 (0-10)	<0.001
Normal	2.86±2.99	2 (0-12)		1.01±1.67	0 (0-12)	
Overweighed	2.51±2.72	2 (0-12)		0.80±1.47	0 (0-10)	
Obese	2.66±2.80	2 (0-12)		0.86±1.57	0 (0-12)	
Influenza vaccination						
No	2.69±2.88	2 (0-12)	0.036	0.87±1.56	0 (0-12)	<0.001
Yes	2.79±2.82	2 (0-12)		1.01±1.60	0 (0-10)	
Pneumococcal vaccination						
No	2.73±2.87	2 (0-12)	0.339	0.92±1.58	0 (0-12)	0.436
Yes	2.74±2.75	2 (0-12)		0.93±1.53	0 (0-10)	

*Low (BMI<20 kg/m²), Normal (BMI: 20-24.9 kg/m²), Overweighed (BMI: 25-29.9 kg/m²), Obese (BMI ≥ 30 kg/m²). BMI=Body mass index, SD=Standard deviation, GOLD=Global Initiative for Chronic Obstructive Pulmonary Disease

France (73%, during 2010/2011 season).^[21,22] More acceptable vaccination rates were reported from Spain in 2003 for influenza (84.2%) and for pneumococcus (65%).^[23] However, a recent study reported a small decrease in overall prevalence of influenza vaccination (62.7%) in Spain.^[24]

Patients with older age, higher level of education, more severe COPD, and comorbidities and patients who were

ex-smokers and residing in urban areas had higher rates of influenza vaccination. Similarly, ex-smokers, patients with a higher level of education and comorbidities, patients residing in urban area, and also female patients had higher rates of pneumococcus vaccination. Similar to our results, the vaccination rates were found to be higher among the higher educational levels,^[16,20,24-27] elder patients and those with concomitant disease,^[16,19,21] and were found to be lower among active smokers.^[17,19,21]

Ariñez-Fernandez *et al.* also concluded that the most important determinants of pneumococcus vaccination are female gender, advanced age, and severity of COPD.^[28] In addition to the some demographical characteristics, vaccine recommendation by physician seems to be an important determinant of vaccination. We detected that, of the patients being vaccinated, 86.3% reported that they took into consideration of their physician's advice, while 53.1% of patients being unvaccinated reported that their physician gave no advice. Some studies also emphasize the importance of physicians' recommendation in vaccination rates.^[16,22] However, some other studies underline the role of patients not believing the effectiveness of vaccines.^[29]

Our study showed that the annual number of COPD exacerbations requiring physician/outpatient visits or hospitalizations (2.73 ± 2.85 and 0.92 ± 1.58 , respectively) was higher than those previous studies.^[30,31] For example, in the TORCH and the UPLIFT studies, the annual rate of exacerbations was 0.85 and 0.73 in treatment groups and 1.13 and 0.85 in placebo groups, respectively.^[30,31] Our results also showed that patients with older age (>65), lower education levels, more severe COPD, comorbid diseases and lower BMI, patients who are male, and patients who are residing in rural area and vaccinated for influenza had significantly higher rates of COPD exacerbation. Although we did not investigate the role of prior exacerbations, analysis of the ECLIPSE study showed that the single best predictor of exacerbations, across all GOLD stages, was a past history of exacerbations.^[32] Consistent to our results, increasing age, severity of airflow limitation, prior asthma diagnosis, eosinophilia, and comorbid conditions were also previously confirmed to be predictors of frequent exacerbations.^[33-37] On the contrary, we showed that higher levels of education and residence in urban areas were found to be associated with reduced risk of exacerbation. The association between higher level of education and less exacerbation rate was not surprising as well as the residential area. We believe that the lower rates of exacerbations in residents of urban areas are mostly associated with more viable and comfortable living conditions and a higher quality of life. Thus, Suzuki *et al.* and Hurst *et al.* reported poorer quality of life to be associated with frequent exacerbations.^[33,34] On the other hand, we think that the higher rates COPD exacerbations in patients vaccinated for influenza might be associated with the tendency of vaccination among more severe COPD patients.

Our study has some limitations. Despite high number of study population, our data are mostly dependent on self-reporting of vaccination and exacerbation rates. The validity of self-reported vaccination status has not been assessed in Turkish population; however, some studies

reported that self-reported vaccination status is adequate in Australian and American patients.^[38,39] On the other hand, especially recall of pneumococcal vaccination may be difficult since it is performed >5 years intervals (until this study, only polysaccharide type [PPSV23] was available). Similar to vaccination status, number of exacerbations and hospitalizations especially in frequent exacerbators might be difficult to remember.

Conclusions

Our results demonstrated that influenza and pneumococcal vaccination rates remained suboptimal during 2013–2014 season among COPD patients and the number of annual outpatient visits and hospitalizations due to COPD exacerbations was high in Turkey. Advanced age, higher education levels, presence of comorbidities, higher COPD stages, and exacerbation rates were associated with both influenza and pneumococcal vaccination.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic obstructive pulmonary disease surveillance – United states, 1971-2000. *MMWR Surveill Summ* 2002;51:1-6.
2. Menezes AM, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G, *et al.* Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): A prevalence study. *Lancet* 2005;366:1875-81.
3. de Marco R, Accordini S, Cerveri I, Corsico A, Sunyer J, Neukirch F, *et al.* An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. *Thorax* 2004;59:120-5.
4. Tzanakis N, Anagnostopoulou U, Filaditaki V, Christaki P, Siafakas N; COPD group of the Hellenic Thoracic Society, *et al.* Prevalence of COPD in Greece. *Chest* 2004;125:892-900.
5. Peña VS, Miravittles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, *et al.* Geographic variations in prevalence and underdiagnosis of COPD: Results of the IBERPOC multicentre epidemiological study. *Chest* 2000;118:981-9.
6. Buist AS, Vollmer WM, McBurnie MA. Worldwide burden of COPD in high- and low-income countries. Part I. The burden of obstructive lung disease (BOLD) initiative. *Int J Tuberc Lung Dis* 2008;12:703-8.
7. Baykal Y. An epidemiological investigation on chronic obstructive pulmonary disease. *Tuberk Toraks* 1976;24:3-18.
8. Acican T, Gulbay BE. Acute exacerbation of chronic obstructive pulmonary disease (COPD). *Turk Klin J Surg Med Sci* 2006;2:40-4.
9. MacNee W. Acute exacerbations of COPD. *Swiss Med Wkly* 2003;133:247-57.
10. Sethi S. Infectious etiology of acute exacerbations of chronic bronchitis. *Chest* 2000;117:380S-5S.
11. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality

- in elderly persons with chronic lung disease. *Ann Intern Med* 1999;130:397-403.
12. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2006;1:CD002733.
 13. Alfageme I, Vazquez R, Reyes N, Muñoz J, Fernández A, Hernandez M, *et al.* Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. *Thorax* 2006;61:189-95.
 14. Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. *Cochrane Database Syst Rev* 2017;1:CD001390.
 15. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2017.
 16. Aka Aktürk Ü, Görek Dilektaşlı A, Şengül A, Musaffa Salepçi B, Oktay N, Düger M, *et al.* Influenza and pneumonia vaccination rates and factors affecting vaccination among patients with chronic obstructive pulmonary disease. *Balkan Med J* 2017;34:206-11.
 17. Bülbül Y, Öztuna F, Gülsoy A, Özlü T. Chronic obstructive pulmonary disease in Eastern black sea region: Characteristics of the disease and the frequency of influenza-pneumococcal vaccination. *Turk Klin J Med Sci* 2010;30:24-9.
 18. López Varela MV, Muiño A, Pérez Padilla R, Jardim JR, Tálamo C, Montes de Oca M, *et al.* Treatment of chronic obstructive pulmonary disease in 5 Latin American cities: The PLATINO study. *Arch Bronconeumol* 2008;44:58-64.
 19. Chiatti C, Barbadoro P, Marigliano A, Ricciardi A, Di Stanislao F, Prospero E, *et al.* Determinants of influenza vaccination among the adult and older Italian population with chronic obstructive pulmonary disease: A secondary analysis of the multipurpose ISTAT survey on health and health care use. *Hum Vaccin* 2011;7:1021-5.
 20. Schoefer Y, Schaberg T, Raspe H, Schaefer T. Determinants of influenza and pneumococcal vaccination in patients with chronic lung diseases. *J Infect* 2007;55:347-52.
 21. Eagan TM, Hardie JA, Jul-Larsen Å, Grydeland TB, Bakke PS, Cox RJ, *et al.* Self-reported influenza vaccination and protective serum antibody titers in a cohort of COPD patients. *Respir Med* 2016;115:53-9.
 22. Vandenbos F, Gal J, Radicchi B. Vaccination coverage against influenza and pneumococcus for patients admitted to a pulmonary care service. *Rev Mal Respir* 2013;30:746-51.
 23. Jiménez-García R, Ariñez-Fernandez MC, Hernández-Barrera V, García-Carballo MM, de Miguel AG, Carrasco-Garrido P, *et al.* Compliance with influenza and pneumococcal vaccination among patients with chronic obstructive pulmonary disease consulting their medical practitioners in Catalonia, Spain. *J Infect* 2007;54:65-74.
 24. Garrastazu R, García-Rivero JL, Ruiz M, Helguera JM, Arenal S, Bonnardeux C, *et al.* Prevalence of influenza vaccination in chronic obstructive pulmonary disease patients and impact on the risk of severe exacerbations. *Arch Bronconeumol* 2016;52:88-95.
 25. Lu PJ, Singleton JA, Rangel MC, Wortley PM, Bridges CB. Influenza vaccination trends among adults 65 years or older in the United States, 1989-2002. *Arch Intern Med* 2005;165:1849-56.
 26. Jiménez-García R, Hernández-Barrera V, Carrasco-Garrido P, de Andrés AL, de Miguel Díez J, de Miguel AG, *et al.* Coverage and predictors of adherence to influenza vaccination among Spanish children and adults with asthma. *Infection* 2010;38:52-7.
 27. Santaularia J, Hou W, Perveen G, Welsh E, Faseru B. Prevalence of influenza vaccination and its association with health conditions and risk factors among Kansas adults in 2013: A cross-sectional study. *BMC Public Health* 2016;16:185.
 28. Ariñez-Fernandez MC, Carrasco-Garrido P, García-Carballo M, Hernández-Barrera V, de Miguel AG, Jiménez-García R, *et al.* Determinants of pneumococcal vaccination among patients with chronic obstructive pulmonary disease in Spain. *Hum Vaccin* 2006;2:99-104.
 29. Ciblak MA; Grip Platformu. Influenza vaccination in Turkey: Prevalence of risk groups, current vaccination status, factors influencing vaccine uptake and steps taken to increase vaccination rate. *Vaccine* 2013;31:518-23.
 30. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, *et al.* Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. *N Engl J Med* 2007;356:775-89.
 31. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, *et al.* A 4-year trial of tiotropium in chronic obstructive pulmonary disease. *N Engl J Med* 2008;359:1543-54.
 32. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA, *et al.* Temporal clustering of exacerbations in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2009;179:369-74.
 33. Suzuki M, Makita H, Ito YM, Nagai K, Konno S, Nishimura M, *et al.* Clinical features and determinants of COPD exacerbation in the Hokkaido COPD cohort study. *Eur Respir J* 2014;43:1289-97.
 34. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, *et al.* Susceptibility to exacerbation in chronic obstructive pulmonary disease. *N Engl J Med* 2010;363:1128-38.
 35. Montes de Oca M, Tálamo C, Halbert RJ, Perez-Padilla R, Lopez MV, Muiño A, *et al.* Frequency of self-reported COPD exacerbation and airflow obstruction in five Latin American cities: The Proyecto Latinoamericano de Investigacion en Obstruccion Pulmonar (PLATINO) study. *Chest* 2009;136:71-8.
 36. Husebø GR, Bakke PS, Aanerud M, Hardie JA, Ueland T, Grønseth R, *et al.* Predictors of exacerbations in chronic obstructive pulmonary disease – Results from the Bergen COPD cohort study. *PLoS One* 2014;9:e109721.
 37. Kerkhof M, Freeman D, Jones R, Chisholm A, Price DB; Respiratory Effectiveness Group, *et al.* Predicting frequent COPD exacerbations using primary care data. *Int J Chron Obstruct Pulmon Dis* 2015;10:2439-50.
 38. Skull SA, Andrews RM, Byrnes GB, Kelly HA, Nolan TM, Brown GV, *et al.* Validity of self-reported influenza and pneumococcal vaccination status among a cohort of hospitalized elderly inpatients. *Vaccine* 2007;25:4775-83.
 39. Irving SA, Donahue JG, Shay DK, Ellis-Coyle TL, Belongia EA. Evaluation of self-reported and registry-based influenza vaccination status in a Wisconsin cohort. *Vaccine* 2009;27:6546-9.

*RIMPACT Study Investigators

Okutan O¹, Yildiz BP², Cetinkaya PD³, Arslan S⁴, Cakmak G⁵, Cirak AK⁶, Sarioglu N⁷, Kocak ND⁸, Akturk UA⁸, Demir M⁹, Kilic T¹⁰, Dalli A¹¹, Hezer H¹², Altintas N¹³, Acat M¹⁴, Dagli CE¹⁵, Kargi A¹⁶, Yakar F¹⁷, Kirkil G¹⁸, Baccioglu A¹⁹, Gedik C²⁰, Intepe YS²¹, Karadeniz G⁶, Onyilmaz T²², Saylan B²³, Baslilar S²³, Sariman N²⁴, Ozkurt S²⁵, Arinc S⁸, Kanbay A²⁰, Yazar EE², Yildirim Z²⁶, Kadioglu EE²⁷, Gul S², Sengul A²⁸, Berk S⁴, Dikis OS²⁹, Kurt OK¹⁶, Arslan Y³⁰, Erol S⁶, Korkmaz C³¹, Balaban A³², Toru Erbay U³³, Sogukpinar O⁸, Uzaslan EK³⁴, Babaoglu E¹², Bahadir A², Baris SA³⁵, Ugurlu AO³⁶, Ilgazli AH³⁵, Fidan F³⁷, Kararmaz E³⁸, Guzel A³⁹, Alzafer S⁴⁰, Cortuk M¹⁴, Hocanli I⁴¹, Ortakoylu MG², Erginel MS⁴², Yaman N⁴³, Erbaycu AE⁶, Demir A⁶, Duman D⁸, Tanriverdi H⁴⁴, Yavuz MY⁶, Sertogullarindan B⁴⁵, Ozyurt S⁴⁶, Bulcun E¹⁹, Yuce GD⁴⁷, Sariaydin M⁴⁸, Ayten O¹, Bayraktaroglu M², Tekgul S⁶, Erel F⁷, Senyigit A⁹, Kaya SB¹⁰, Ayik S¹¹, Yazici O¹⁴, Akgedik A¹⁵, Yasar ZA¹⁶, Hayat E¹⁷, Kalpaklioglu F¹⁹, Sever F⁶, Sarac P²², Ugurlu E²⁵, Kasapoglu US⁸, Gunluoglu G², Demirci NY²⁶, Bora M²⁹, Talay F¹⁶, Ozkara B³⁰, Yilmaz MU⁶, Yavsan DM³¹, Cetinoglu ED³⁴, Balcan MB³⁶, Ciftci T³⁵, Havan A³⁷, Gok A³⁹, Nizam M²

¹Haydarpaşa Hospital of Gulhane Military Medical Academy Department of Chest Diseases, Istanbul, Pulmonary Diseases and Thoracic Surgery Education and Research Hospitals of ²Yedikule, Istanbul, ⁶Dr. Suat Seren, Izmir and ⁸Sureyyapasa, Istanbul, Education and Research Hospitals of ³Numune, Adana, ⁵Haseki, Istanbul, ¹²Ataturk, Ankara, ²³Umraniye, Istanbul, ²⁷Regional, Erzurum, ²⁸Derince, Kocaeli, ²⁹Sevket Yilmaz, Bursa, ³²Evliya Celebi, Kutahya, ⁴⁷Diskapi Yildirim Beyazid, Ankara. Departments of Chest Diseases School of Medicine ⁴Cumhuriyet University, Sivas, ⁷Balikesir University, Balikesir, ⁹Dicle University, Diyarbakir, ¹⁰Inonu University, Malatya, ¹¹Katip Celebi University, Izmir, ¹³Namik Kemal University, Tekirdag, ¹⁴Karabuk University, Karabuk, ¹⁵Ordu University, Ordu, ¹⁶Abant Izzet Baysal University, Bolu, ¹⁷Bezmialem Vakıf University, Istanbul, ¹⁸Firat University, Elazig, ¹⁹Kirikkale University, Kirikkale, ²⁰Medeniyet University, Istanbul, ²¹Bozok University, Yozgat, ²⁴Maltepe University, Istanbul, ²⁵Pamukkale University, Denizli, ²⁶Gazi University, Ankara, ³¹Necmettin Erbakan University, Konya, ³³Dumlupinar University, Kutahya, ³⁴Uludag University, Bursa, ³⁵Kocaeli University, Kocaeli, ³⁷Fatih University, Istanbul, ³⁹Ondokuz Mayıs University, Samsun, ⁴⁰Acibadem University Bakirköy Hospital, Istanbul. ⁴²Osmangazi University, Eskisehir, ⁴⁴Bulent Ecevit University, Zonguldak, ⁴⁵Yuzuncü Yil University, Van, ⁴⁶Recep Tayyip Erdogan University, Rize, ⁴⁸Kocatepe University, Afyon, State Hospitals of ²²Mardin, Mardin, ³⁸Toros, Adana, ⁴¹Sirnak, Sirnak. ³⁰Etimesgut Military Hospital, Ankara, ³⁶Baskent University Istanbul Hospital, Istanbul, ⁴³Pulmonary Diseases Hospital, Balikesir, Turkey